As Delhi’s AQI hits a new high, it is essential to know the effect it can have on our skin. Know the preventive measures from ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

The following is a summary of “Identification of risk factors associated with metabolic dysfunction-associated steatotic liver disease in psoriatic patients,” published in the November 2024 issue of ...

Johnson & Johnson (J&J) has reported positive topline outcomes from its Phase III ICONIC-LEAD trial of oral icotrokinra ...

Vista, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced a strategic partnership with the National Psoriasis ...

Stay informed with Hindustan Times' live updates! Track the latest lifestyle news including fashion trends, style guide & ...

The once-daily pill, icotrokinra, was tested in patients with moderate-to-severe plaque psoriasis, a skin condition that ...

Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effectsSupports therapeutic ...

Johnson & Johnson's drug for a type of skin condition met the main goals in a late-stage trial, the drugmaker said on Monday.

If you're dealing with chronic skin conditions, such as eczema or psoriasis, your skin is more vulnerable to environmental changes so you might also be more likely to get itchy skin during chilly ...

Diabetes mellitus is a common, chronic metabolic disease that affects a variety of organs including the skin, the largest organ in the body. Between 30 and 70 percent of people ...

In the ICONIC-LEAD study, once-daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis. At week 16, nearly two-thirds of ...